<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Vestnik dermatologii i venerologii</journal-id><journal-title-group><journal-title xml:lang="en">Vestnik dermatologii i venerologii</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник дерматологии и венерологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0042-4609</issn><issn publication-format="electronic">2313-6294</issn><publisher><publisher-name xml:lang="en">Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">277</article-id><article-id pub-id-type="doi">10.25208/0042-4609-2016-92-5-96-101</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>DRUG TREATMENT IN DERMATOVENEROLOGY</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ФАРМАКОТЕРАПИЯ В ДЕРМАТОВЕНЕРОЛОГИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experience destructive therapy anogenital warts</article-title><trans-title-group xml:lang="ru"><trans-title>Опыт деструктивной терапии аногенитальных бородавок</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rahmatulina</surname><given-names>M. R.</given-names></name><name xml:lang="ru"><surname>Рахматулина</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Nechaeva</surname><given-names>I. A.</given-names></name><name xml:lang="ru"><surname>Нечаева</surname><given-names>И. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>i.nechaeva76@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shalva</surname><given-names>Mardi</given-names></name><name xml:lang="ru"><surname>Шалва</surname><given-names>Марди</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Center of Dermatovenereology and Cosmetology, Ministry of Healthcare of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБУ «Государственный научный центр дерматовенерологии и косметологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Cabinet of Dr. Shalva Mardi</institution></aff><aff><institution xml:lang="ru">Кабинет доктора Шалвы Марди</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2016-10-24" publication-format="electronic"><day>24</day><month>10</month><year>2016</year></pub-date><volume>92</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>96</fpage><lpage>101</lpage><history><date date-type="received" iso-8601-date="2017-08-24"><day>24</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2016, Rahmatulina M.R., Nechaeva I.A., Shalva M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2016, Рахматулина М.Р., Нечаева И.А., Шалва М.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="en">Rahmatulina M.R., Nechaeva I.A., Shalva M.</copyright-holder><copyright-holder xml:lang="ru">Рахматулина М.Р., Нечаева И.А., Шалва М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnikdv.ru/jour/article/view/277">https://vestnikdv.ru/jour/article/view/277</self-uri><abstract xml:lang="en"><p>Objective. To assess the efficiency and tolerability of the Mardil Zinc Max, solution for external application, in topical therapy of patients with anogenital warts. Materials and methods. The study involved 58 women and 12 men at the age of 18 to 57 years old, suffering from anogenital warts. the diagnosis was confirmed by identification of human papillomavirus by the polymerase chain reaction in real time. All the patients were treated by the chemical destruction of anogenital warts with the 1.5% solution of zinc chloropropionate in 50% 2-chloropropionic acid (Mardil Zinc Max) by a single application of the solution on the pathological eruptions. The results of treatment were assessed in 2 weeks, in 1, 3, 6 and 9 months after the destructive therapy. Results. In 2 weeks 62 (88.6%) patients showed a clinical cure with complete tissue regeneration in the lesions, in 8 (11,4%) cases in areas of the preparation erosions were visualized in the epithelialization phase, and they completely resolved within 1 week. recurrences of anogenital warts were detected in 1 (1,4%) patient in the observation period up to 3 months and in 2 (2,8%) patients during 9 months after carrying out the destruction. Adverse drug events have not been identified in the course of therapy and follow-up. Conclusions. As a result of the treatment of anogenital warts with the Mardil Zinc Max high rate of performance and security was set (100%), as well as the low percentage (4,2%) of development of relapses.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Оценить эффективность и переносимость препарата Мардил Цинк Макс, раствор для наружного применения, в топической терапии больных аногенитальными бородавками. Материал и методы. В исследование включены 58 женщин и 12 мужчин в возрасте от 18 до 57 лет, больных аногенитальными бородавками. Диагноз подтверждался идентификацией вирусов папилломы человека методом полимеразной цепной реакции в режиме реального времени. Всем больным проводилась химическая деструкция аногенитальных бородавок 1,5% раствором цинка 2-хлорпропионата в 50% 2-хлорпропионовой кислоте (Мардил Цинк Макс) путем однократного нанесения раствора на патологические высыпания. Результаты лечения оценивались через 2 нед., 1, 3, 6 и 9 мес. после проведенной деструктивной терапии. Результаты. Через 2 нед. у 62 (88,6%) больных наблюдалось клиническое излечение с полной регенерацией тканей в очагах поражения, у 8 (11,4%) больных в зонах нанесения препарата визуализировались эрозии в стадии эпителизации, которые полностью разрешились в течение 1 нед. Рецидивы аногенитальных бородавок регистрировались у 1 (1,4%) пациента в период наблюдения до 3 мес. и у 2 (2,8%) пациентов в течение 9 мес. после проведения деструкции. Нежелательных лекарственных явлений в процессе терапии и последующего наблюдения не выявлено. Заключение. В результате терапии аногенитальных бородавок препаратом Мардил Цинк Макс установлены высокие показатели эффективности (100%) и безопасности, а также низкий процент (4,2%) развития рецидивов заболевания.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>папилломавирусная инфекция</kwd><kwd>аногенитальные бородавки</kwd><kwd>вирус папилломы человека</kwd><kwd>наружная терапия</kwd><kwd>химическая деструкция</kwd><kwd>Мардил Цинк Макс</kwd><kwd>human papillomavirus infection</kwd><kwd>anogenital warts</kwd><kwd>human papillomavirus (HPV)</kwd><kwd>topical therapy</kwd><kwd>chemical destruction</kwd><kwd>Mardil Zinc Max</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Mendes D., Bains I., Vanni T., Jit M. Systematic review of model-based cervical screening evaluations. BMC Cancer 2015 May; 1: 315-334.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Arbyn M., Ronco G., Anttila A., Meijer C.J., Poljak M., Ogilvie G., Koliopoulos G., Naucler P., Sankaranarayanan R., Peto J. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012 Nov; 20: 30 (5): 88-99.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Cuzick J., Bergeron C., von Knebel Doeberitz M., Gravitt P., Jeronimo J., Lorincz A.T., J L M Meijer C., Sankaranarayanan R., J F Snijders P., Szarewski A. New technologies and procedures for cervical cancer screening. Vaccine 2012 Nov; 20; 30 (5): 107-116.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Goldie S.J., Kim J.J., Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine 2006 Aug; 31; 24 (3): 164-170.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Del Mistro A. HPV genotyping in the prevention of cervical cancer - how and when can it be a useful marker? Cancer Epidemiol Biomarkers Prev 2015 Jun; 18.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Cheng S., Hua Y., Mu X., Liu C. Infection status of cervical human papilloma virus in patients with cervical intraepithelial neoplasia. Zhonghua Yi Xue Za Zhi 2015 Mar; 24; 95 (11): 857-859.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Tavares M.C., de Lima Junior S.F., Coelho A.V., Marques T.R., de Araujo D.H., Heraclio S.A., Amorim M.M., de Souza P.R., Crovella S. Ann Hum Biol 2015 Jun; 16: 1-8.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Prabhavathy D., Subramanian C.K., Karunagaran D. Re-expression of HPV16 E2 in SiHa (human cervical cancer) cells potentiates NF-kB activation induced by TNF-a concurrently increasing senescence and survival. Biosci Rep 2015 Feb; 25; 35 (1).</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kim K.Y., Blatt L., Taylor M.W. The effects of interferon on the expression of human papillomavirus oncogenes. J Gen Virol 2000 Mar; 81 (Pt 3): 695-700.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Aguilar-Martinez E., Morrisroe C., Sharrocks A.D. The ubiquitin ligase UBE3A dampens ERK pathway signalling in HPV E6 transformed HeLa cells. PLoS One 2015 Mar; 27; 10 (3).</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Holloway A., Simmonds M., Azad A., Fox J.L., Storey A. Resistance to UV-induced apoptosis by ß-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase. Int J Cancer 2015 Jun; 15; 136 (12): 2831-2843.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Jing K., Shin S., Jeong S., Kim S., Song K.S., Park J.H., Heo J.Y., Seo K.S., Park S.K., Kweon G.R., Wu T., Park J.I., Lim K. Docosahexaenoic acid induces the degradation of HPV E6/E7 oncoproteins by activating the ubiquitin-proteasome system. Cell Death Dis 2014 Nov; 13; 5: 1524.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Rob F., Kruzicova Z., Vanousova D., Hercogova J. Condylomata acuminata (genital warts). Ceska Gynekol 2014 Fall; 79 (5): 399-406.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Steben M., Garland S.M. Genital warts. Best Pract Res Clin Obstet Gynaecol 2014 Oct; 28 (7): 1063-73.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Richards S. An overview of genital warts. Nurs Stand 2014 Feb; 12-18; 28 (24): 46-50.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Huang J., Zeng Q., Zuo C., Yang S., Xiang Y., Lu J., Kang J., Tan L., Yu X., Xi C., Huang J., Kang L., Fan F., Chen J. The combination of CO2 laser vaporation and photodynamic therapy in treatment of condylomata acuminata. Photodiagnosis Photodyn Ther 2014 Jun; 11 (2): 130-133.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lopez-Lopez D., Agrasar-Cruz C., Bautista-Casasnovas A., Älvarez-Castro C.J. Application of cantharidin, podophyllotoxin, and salicylic acid in recalcitrant plantar warts. A preliminary study. Gac Med Mex 2015 Jan-Feb; 151 (1): 14-19.</mixed-citation></ref></ref-list></back></article>
